Role of insulin-like growth factor 1 and phosphoinositide 3-kinase in a setting of heart disease

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 3, 2008, Pages 349-354

  McMullen, Julie R ^a,b  

^a Baker Heart Research Institute ^*  (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cardiac hypertrophy; Cardioprotection; Heart failure

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C;

DRUG EFFECT; DRUG MECHANISM; GENETIC MODEL; HEART CONTRACTION; HEART DISEASE; HEART FAILURE; LIFESPAN; NONHUMAN; REGENERATION; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; HEART DISEASES; HUMANS; INSULIN-LIKE GROWTH FACTOR I;

EID: 39149118347     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04873.x     Document Type: Review

References (56)

1. Toker A, Cantley LC. Signalling through the lipid products of phosphoinositide-3-OH kinase. Nature 1997 387 : 673 6.
2. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: A conserved family of signal transducers. Trends Biochem. Sci. 1997 22 : 267 72.
3. Conlon I, Raff M. Size control in animal development. Cell 1999 96 : 235 44.
4. Leevers SJ, Weinkove D, MacDougall LK, Hafen E, Waterfield MD. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 1996 15 : 6584 94.
5. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990 345 : 78 80.
6. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993 75 : 73 82.
7. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993 75 : 59 72.
8. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J. Biol. Chem. 1999 274 : 10 963 8.
9. Fruman DA, Snapper SB, Yballe CM et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 1999 283 : 393 7.
10. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: Physiological and pathophysiological implications in heart disease. J. Mol. Cell. Cardiol. 1999 31 : 2049 61.
11. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure. Clin. Exp. Pharmacol. Physiol. 2007 34 : 255 62.
12. Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Prog. Cardiovasc. Dis. 1974 17 : 5 24.
13. Zak R. Growth of the Heart in Health and Disease. Raven Press, New York. 1984.
14. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors. The Framingham Heart Study. Ann. Intern. Med. 1988 108 : 7 13.
15. Cohn JN, Bristow MR, Chien KR et al. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on heart failure research. Circulation 1997 95 : 766 70.
16. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 1990 322 : 1561 6.
17. Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE. The athlete's heart. A meta-analysis of cardiac structure and function. Circulation 2000 101 : 336 44.
18. Fagard RH. Impact of different sports and training on cardiac structure and function. Cardiol. Clin. 1997 15 : 397 412.
19. Neri Serneri GG, Boddi M, Modesti PA et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ. Res. 2001 89 : 977 82.
20. Koziris LP, Hickson RC, Chatterton Jr. RT et al. Serum levels of total and free IGF-I and IGFBP-3 are increased and maintained in long-term training. J. Appl. Physiol. 1999 86 : 1436 42.
21. Yeh JK, Aloia JF, Chen M, Ling N, Koo HC, Millard WJ. Effect of growth hormone administration and treadmill exercise on serum and skeletal IGF-I in rats. Am. J. Physiol. 1994 266 : E129 35.
22. Frey N, Olson EN. Cardiac hypertrophy: The good, the bad, and the ugly. Annu. Rev. Physiol. 2003 65 : 45 79.
23. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell. Biol. 2006 7 : 589 600.
24. Reiss K, Cheng W, Ferber A et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc. Natl Acad. Sci. USA 1996 93 : 8630 5.
25. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. Cardiomyocyte DNA synthesis and binucleation during murine development. Am. J. Physiol. 1996 271 : H2183 9.
26. Delaughter MC, Taffet GE, Fiorotto ML, Entman ML, Schwartz RJ. Local insulin-like growth factor I expression induces physiologic, then pathologic, cardiac hypertrophy in transgenic mice. FASEB J. 1999 13 : 1923 9.
27. Fiorotto ML, Schwartz RJ, Delaughter MC. Persistent IGF-I overexpression in skeletal muscle transiently enhances DNA accretion and growth. FASEB J. 2003 17 : 59 60.
28. McMullen JR, Shioi T, Huang WY et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-Kinase (p110{alpha}) pathway. J. Biol. Chem. 2004 279 : 4782 93.
29. Shioi T, Kang PM, Douglas PS et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000 19 : 2537 48.
30. McMullen JR, Shioi T, Zhang L et al. Phosphoinositide 3-kinase (p110{alpha}) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 2003 100 : 12 355 60.
31. Luo J, McMullen JR, Sobkiw CL et al. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 2005 25 : 9491 502.
32. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ. Res. 1998 83 : 516 22.
33. Welch S, Plank D, Witt S et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ. Res. 2002 90 : 641 8.
34. Li B, Setoguchi M, Wang X et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ. Res. 1999 84 : 1007 19.
35. Kajstura J, Fiordaliso F, Andreoli AM et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 2001 50 : 1414 24.
36. Li Q, Li B, Wang X et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J. Clin. Invest. 1997 100 : 1991 9.
37. McMullen JR, Amirahmadi F, Woodcock EA et al. Protective effects of exercise and phosphoinositide 3-kinase (p110{alpha}) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 2007 104 : 612 17.
38. Hill M, Goldspink G. Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage. J. Physiol. 2003 549 : 409 18.
39. Rosenthal N, Musaro A. Gene therapy for cardiac cachexia? Int. J. Cardiol. 2002 85 : 185 91.
40. Santini MP, Winn N, Rosenthal N. Signalling pathways in cardiac regeneration. Novartis Found. Symp. 2006 274 : 228 38.
41. Shiraishi I, Melendez J, Ahn Y et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 2004 94 : 884 91.
42. DeBosch B, Treskov I, Lupu TS et al. Akt1 is required for physiological cardiac growth. Circulation 2006 113 : 2097 104.
43. McMullen JR, Amirahmadi F, Woodcock EA et al. Protective effects of exercise and PI3K (p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 2007 104 : 612 17.
44. 2+ homeostasis and cardiac contractility. J. Mol. Cell. Cardiol. 2001 33 : 1053 63.
45. Carter CS, Ramsey MM, Sonntag WE. A critical analysis of the role of growth hormone and IGF-1 in aging and lifespan. Trends Genet. 2002 18 : 295 301.
46. Wessells RJ, Fitzgerald E, Cypser JR, Tatar M, Bodmer R. Insulin regulation of heart function in aging fruit flies. Nat. Genet. 2004 36 : 1275 81.
47. Broughton SJ, Piper MD, Ikeya T et al. Longer lifespan, altered metabolism, and stress resistance in Drosophila from ablation of cells making insulin-like ligands. Proc. Natl Acad. Sci. USA 2005 102 : 3105 10.
48. Arantes-Oliveira N, Berman JR, Kenyon C. Healthy animals with extreme longevity. Science 2003 302 : 611.
49. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003 299 : 572 4.
50. Holzenberger M, Dupont J, Ducos B et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003 421 : 182 7.
51. Anversa P. Aging and longevity: The IGF-1 enigma. Circ. Res. 2005 97 : 411 14.
52. Cittadini A, Cuocolo A, Merola B et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am. J. Physiol. 1994 267 : E219 25.
53. Merola B, Cittadini A, Colao A et al. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J. Clin. Endocrinol. Metab. 1993 77 : 1658 61.
54. Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin. Endocrinol. 2001 54 : 137 54.
55. Marleau S, Mulumba M, Lamontagne D, Ong H. Cardiac and peripheral actions of growth hormone and its releasing peptides: Relevance for the treatment of cardiomyopathies. Cardiovasc. Res. 2006 69 : 26 35.
56. McMullen JR, Jay PY. PI3K (p110alpha) inhibitors as anti-cancer agents: Minding heart. Cell Cycle 2007 6 : 910 13.